ADMA Biologics Inc $ADMA Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 15.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,613 shares of the biotechnology company’s stock after acquiring an additional 1,024 shares during the quarter. GAMMA Investing LLC’s holdings in ADMA Biologics were worth $139,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Cetera Investment Advisers lifted its stake in shares of ADMA Biologics by 1.3% in the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock worth $1,002,000 after acquiring an additional 670 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company’s stock worth $1,323,000 after acquiring an additional 711 shares in the last quarter. GF Fund Management CO. LTD. increased its holdings in ADMA Biologics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,089 shares during the last quarter. Journey Strategic Wealth LLC raised its stake in ADMA Biologics by 6.6% during the first quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 1,102 shares in the last quarter. Finally, KBC Group NV raised its stake in ADMA Biologics by 11.5% during the first quarter. KBC Group NV now owns 11,217 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 1,154 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Trading Down 0.3%

Shares of NASDAQ ADMA opened at $14.66 on Wednesday. The stock’s 50 day moving average price is $16.92 and its two-hundred day moving average price is $18.84. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The stock has a market capitalization of $3.50 billion, a P/E ratio of 17.05 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $121.98 million for the quarter, compared to analysts’ expectations of $121.77 million. During the same quarter in the prior year, the firm posted $0.13 earnings per share. ADMA Biologics’s revenue for the quarter was up 13.8% compared to the same quarter last year. On average, analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.